Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

Código QR

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

Takeshi Osonoi, Miyoko Saito, Naoya Koda, Satako Douguchi, Takako Nakano, Kensuke Ofuchi, Makoto Katoh Naka Kinen Clinic, Ibaraki, JapanCorrespondence: Makoto KatohNaka Kinen Clinic, 745-5 Nakadai, Naka-Shi, Ibaraki 311-0113, JapanTel +81-29-353-2800Fax +81-29-295-5400Email m-katou@kensei-kai.comPur...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Osonoi T, Saito M, Koda N, Douguchi S, Nakano T, Ofuchi K, Katoh M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	dpp-4 inhibitor α-glucosidase inhibitor metformin egfr slope type 2 diabetes Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/8b5d79d40e3f4f0ba712bb5cf5f548e4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
por: Alexander Sergeevich Ametov, et al.
Publicado: (2010)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
por: Editorial team Diabetes Mellitus
Publicado: (2012)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
por: Karyekar CS, et al.
Publicado: (2013)

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
por: Karina Oganesovna Galstyan, et al.
Publicado: (2016)

Vildagliptin: the first innovative DDP-4 inhibitor
por: Edvin Villkhauer
Publicado: (2010)

DPP-4 Inhibitors Have Different Effects on Endothelial Low-Grade Inflammation and on the M1-M2 Macrophage Polarization Under Hyperglycemic Conditions
por: De Nigris V, et al.
Publicado: (2021)

Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
por: Taehwan Park, et al.
Publicado: (2021)

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
por: Mohammed A. S. Abourehab, et al.
Publicado: (2021)

Design, Synthesis, In Vitro Anticancer Evaluation and Molecular Modelling Studies of 3,4,5-Trimethoxyphenyl-Based Derivatives as Dual EGFR/HDAC Hybrid Inhibitors
por: Tarek S. Ibrahim, et al.
Publicado: (2021)

New Multi-Targeted Antiproliferative Agents: Design and Synthesis of IC261-Based Oxindoles as Potential Tubulin, CK1 and EGFR Inhibitors
por: Momen R. Fareed, et al.
Publicado: (2021)

Health-promoting activities of edible seaweed extracts from Chilean coasts: assessment of antioxidant, anti-diabetic, anti-inflammatory and antimicrobial potential
por: García,Vivian, et al.
Publicado: (2020)

IN VITRO EFFECT OF TERPENOIDS - RICH EXTRACT OF Momordica charantia ON ALPHA GLUCOSIDASE ACTIVITY
por: A. B. SALLAU, et al.

In vitro effect of terpenoid-rich extract of Momordica charantia on alpha glucosidase activity
por: AB SALLAU, et al.
Publicado: (2018)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
por: Lyudmila Viktorovna Nedosugova, et al.
Publicado: (2014)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
por: Kuecker CM, et al.
Publicado: (2016)

Nanozymes as Enzyme Inhibitors
por: Huang Y, et al.
Publicado: (2021)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
por: Taras S. Panevin, et al.
Publicado: (2020)

Linagliptin use in older individuals with type 2 diabetes
por: Pratley RE
Publicado: (2014)

SYNTHESIS AND SAR STRATEGY OF THIAZOLIDINEDIONE: A NOVEL APPROACH FOR CANCER TREATMENT
por: Rashid,Mohammad, et al.
Publicado: (2020)

Diffuse scaly erythematous plaques in patient taking poziotinib
por: Reid Oldenburg, MD, PhD, et al.
Publicado: (2022)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
por: Shen L, et al.
Publicado: (2021)

Teneligliptin in management of type 2 diabetes mellitus
por: Sharma SK, et al.
Publicado: (2016)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
por: Wolfram Samlowski, et al.
Publicado: (2021)

Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma
por: James M. Henderson, et al.
Publicado: (2021)

Protease Inhibitor and Metabolic Alteration
por: Cavenaghi,F. M, et al.
Publicado: (2012)

Effect of Nitrogen Inhibitors on Nitrous Oxide Emissions and Pasture Growth After an Autumn Application in Volcanic Soil
por: Vistoso,Erika, et al.
Publicado: (2012)

Phytochemical Screening and Antioxidant Activity of Seven Native Species Growing in the Forests of Southern Chilean Patagonia
por: Merly de Armas-Ricard, et al.
Publicado: (2021)

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
por: Yu D, et al.
Publicado: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)
por: Sergey V. Kakorin, et al.
Publicado: (2016)

Rannyaya kombinirovannaya terapiya pri sakharnom diabete 2 tipa
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
por: Elena Valer'evna Biryukova
Publicado: (2014)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
por: Ghosh S, et al.
Publicado: (2016)

COX-2 Inhibitors in Dental Pain Management
por: Del-Muro-Casas,Fatima Erendida, et al.
Publicado: (2018)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
por: Kate S, et al.
Publicado: (2019)

Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor
por: Tory Starzyk, MA, et al.
Publicado: (2022)

Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
por: Wiktoria Blaszczak, et al.
Publicado: (2021)

The serine protease inhibitors and plant-insect interaction
por: Mendoza-Blanco,Werner, et al.
Publicado: (2012)